ERBB2 and urinary bladder cancer: DESTINY-PanTumor02 clinical trial, which tested trastuzumab-deruxtecan in Her2+ locally advanced or metastatic solid tumors, includes 41 Her2+ bladder tumors that showed a 56% of objective response rate (ORR) in Her2 IHC3+ and 39% of ORR in all bladder cancer patients [26].